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ABSTRACT 
For over three decades, HIV/AIDS has had a deleterious impact on public health the world over. There is still no cure for the 
disease although preventive strategies have evolved over the years to reduce its impact. In addition to behavioural change 
approaches, biomedical interventions have played a major part in reduction of HIV transmission and subsequently the burden 
associated with the HIV/AIDS disease. Early biomedical approaches include physical barriers such as condoms, use of clean 
injection equipment for intravenous drug users, blood and blood product screening. More recently, medical male circumcision 
and use of anti-retroviral drugs for prevention have been introduced. While these interventions have had a fundamental impact 
in reducing HIV incidence, the burden in many populations remains. Therefore, there is need to develop new biomedical methods 
to augment existing efforts. Future biomedical approaches may for instance include use of compounds that modulate the body’s 
immune system, such as acetylsalicylic acid, to cause resistance to HIV infection. Such approaches could be added to the HIV 
prevention toolkit.  
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INTRODUCTION 
 
The human immunodeficiency virus has been a great threat 
to public health since its discovery in early 1980s (Barre-
Sinoussi et al., 1983). Approximately 36.7 million people 
worldwide were living with HIV/AIDS by the end of 2016 
(UNAIDS, 2016). Although great strides have been made 
towards combating this disease, the number of new HIV 
infections has remained high especially in the last 10 years. 
In 2016 alone, 1.8 million new infections were recorded 
(UNAIDS, 2016). HIV/AIDS thus continues to be a huge 
health, social and economic burden. The advent of 
antiretroviral (ARV) therapy changed the course of HIV 
treatment but an efficacious vaccine or biomedical cure is 
yet to be found. Prevention methods remain the best option 
to bring to a halt HIV transmission. Both primary (to reduce 
incidence) and secondary (to reduce disease prevalence and 
severity) HIV prevention programs employ various 
strategies. Behavioural strategies include education on sex 
and stigma reduction, psycho-social support programs. 
Structural programs such as legislation to reduce gender 
inequalities, stigma and discrimination, economic and 
community empowerment especially for women 
(UNAIDS, 2010) are also incorporated in HIV prevention 
programs. 
 Biomedical methods encompass clinical, medical and 
epidemiological approaches. Earlier biomedical methods 
included physical barrier methods such as condoms; and 
harm reduction methods encompassing injection and 
needle exchanges, opioid substitution therapy, blood and 
blood product screening. More recently voluntary medical 
male circumcision, use of ARVs in treatment as prevention 
(TasP), PMTCT, as well as microbicides and vaccines have 
been developed. Notwithstanding, the need to enhance 
and/or develop new efficacious biomedical preventative 
methods remains a public health priority. Newer frontiers 
for prevention could include strategies that modulate the 
immune system of the body to resist HIV infection. 
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PHYSICAL BARRIER APPROACH 
Condoms, both male and female, provide a physical barrier to 
prevent HIV transmission. Condoms are included as part of 
the ABC (abstinence, being-faithful and condom use) 
initiative employed from early 1980s towards HIV and 
sexually transmitted infections (STIs) prevention. Correct and 
consistent condom use has been shown to decrease hetero-
sexual transmission of HIV-1 (Sánchez et al., 2003) and risk 
of Gonorrhoea and Chlamydia infections (Cohen, 2003). 
Effectiveness of condom use for prevention of HIV 
transmission is dependent on correct and consistent use. 
Overall, among heterosexual persons, condoms have been 
reported to have 64%-94% effectiveness to reduce HIV 
transmission rates. Among men who have sex with men 
(MSM) effectiveness has been reported at 70% (Smith et al., 
2015). A global modelling analysis in 2014 estimated that 
since the beginning of the epidemic, about 50 million new 
HIV infections were averted by use of condoms. However in 
spite of this, condom use does not take into consideration 
persons who do not acquire HIV hetero-sexually such as 
intravenous drug users (IDUs) (Murphy et al., 2006) or those 
unable to negotiate for condom use with their sexual partners. 
 
HARM REDUCTION METHODS 
The notion of reducing harm and subsequently HIV was also 
introduced in early 1980s. IDUs are orally administered with 
replacement drugs such as methadone or buprenorphine in 
opioid substitution therapy programs. This is done in clinical 
settings to wean IDUs off illicit drugs. Aside from helping to 
curb illicit drug use, such measures help reduce HIV risk 
behaviour and improve adherence to ARV treatment 
(UNAIDS, 2010). Clean needle and syringe exchange 
programmes provide IDUs with access to sterile needles and 
syringes as a harm reduction measure, thus reduce 
transmission of HIV and/or other viral blood borne illnesses 
caused by sharing injection equipment (UNAIDS, 2010). In 
hospital settings, screening of blood and blood products before 
transfusion is useful to prevent blood-borne exposure to HIV. 
Overall, harm reduction is a combination of actions including 
HIV education, HIV counselling and testing, that aim to limit 
the exposure to HIV infection.  
 
VOLUNTARY MEDICAL MALE CIRCUMCISION 
(VMMC) 
The penile foreskin predisposes men to HIV acquisition as it 
contains many target cells in its squamous lining, including 
Langerhans’ cells, memory CD4+ T and dendritic cells 
(McCoombe and Short, 2006). Additionally, the foreskin is at 
risk of small tears during sexual intercourse providing a 
potential route of entry for STIs in uncircumcised men (Gray 
et al., 2017). Circumcision, surgical removal of the foreskin, 
has been demonstrated to confer approximately 60% 
protection against HIV acquisition in men (Gray et al., 2017; 
Bailey et al., 2007; Auvert et al., 2005). In light of this, the 
World Health Organisation (WHO) and the Joint United 
Nations Program on HIV/AIDS (UNAIDS) recommended 
addition of voluntary medical male circumcision (VMMC) to 
HIV prevention programs (WHO, 2007) particularly in 
countries with high HIV burden. Though highly effective 
VMMC is not fool proof; it is only one aspect in HIV 
prevention. It should be combined with the promotion of 
condom use, safe sexual practices, STI management, HIV 
testing and counselling (WHO, 2012); and in some cases 
measures such as treatment as prevention and microbicide use. 
 
TREATMENT AS PREVENTION (TasP) 
Since the 1990s, antiretroviral therapy (ART) has been 
effective to manage HIV infection. ART can slow down 
disease progression (WHO, 2015; Kitahata et al., 2009) and 
decrease HIV-1 viral load (Montaner et al., 2011) in blood 
(Gulick et al., 1997), semen (Gupta et al., 1997), rectal fluid 
(Zuckerman et al., 2004, 2007) and vaginal fluid (Cu-Uvin et 
al., 2000). Indeed, initiation of ART early in infection is 
associated with a viral load reduction in the infected person 
and can reduce the rate of transmission to the HIV negative 
partner. TasP can reduce risk of HIV transmission by up to 
96% (Cohen et al., 2011). Furthermore, Rodger et al. (2016) 
reported a zero rate of within-couple transmission from the 
PARTNER study conducted between 2010 and 2014 in which 
the HIV-positive partners from 1 166 sero-discordant couples 
enrolled were put on suppressive ART. Prevention of mother 
to child transmission programs also emphasise the use of ART 
for HIV prevention (Connor et al., 1994; Siegfried et al., 
2011). Indeed, Townsend and colleagues (2008) showed that 
ART administration to pregnant HIV-positive women for only 
two weeks reduced risk of vertical transmission to less than 
1%.  
 Although the working definition of TasP does not include 
use of anti-retroviral drugs (ARVs) for post-exposure 
prophylaxis (PEP), pre-exposure prophylaxis (PrEP) and 
ARV-based microbicides, these strategies have shown 
promise for biomedical prevention strategies. With PEP, 
ARVs are taken for a short duration during the initial hours 
following possible exposure to HIV-1 (Cardo et al., 1997; 
Henderson and Gerberding, 1989). PrEP in contrast uses 
ARVs to protect uninfected individuals before exposure, the 
idea being to interfere with the pathways used by HIV to 
establish an infection.  
 Tenofovir disoproxil fumerate (TDF) and TDF in 
combination with emtricitabine (FTC) (called Truvada®) can 
prevent HIV replication and the establishment of a funder 
population. TDF alone showed a 67% (Baeten et al., 2012) 
and 48.9% (Choopanya et al., 2013) reduction of HIV 
incidence among heterosexual couples and IDUs respectively 
while Truvada® demonstrated a 75% HIV incidence reduction 
among heterosexual sero-discordant couples (Baeten et al., 
2012). Others, the iPrEx study for instance showed that 
Truvada® reduced by 44% the HIV incidence (Grant et al., 
2010) while the PROUD study (McCormack et al., 2017) 
emphasised that the immediate and daily uptake of Truvada® 
is feasible  among a high risk HIV population. Both trials were 
conducted among MSM.  
 In contrast, the FEM-PrEP (Van Damme et al., 2012) and 
VOICE study (Marrazzo et al., 2015), both conducted among 
women, did not show efficacy of PrEP and were prematurely 
terminated. Poor adherence to the intervention protocol and 
the stigma associated with the uptake of ARVs are among 
reasons hypothesised to explain the failure in these specific 
trials (Haire, 2015 ; Mack et al., 2014; Van Der Straten et al., 
2014). Nonetheless, a trial among MSM and female sex 
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workers (FSWs) done in Kenya suggested that an intermittent 
PrEP dosing regimen would be more feasible among higher-
risk groups despite low adherence (Mutua et al., 2012). 
Overall, PrEP using Truvada® is beneficial for HIV prevention 
efforts. Its use has only been approved in 6 countries - 
Botwana, Canada, France, Kenya, Peru, South Africa and 
USA, but many other countries are conducting clinical trials 
to assess feasibility of PrEP for their public health policies per 
local contexts. Unfortunately, high cost, low availability and 
low uptake of Truvada® has been observed as major 
hindrances for worldwide roll-out (WHO, 2015; Williams and 
Gouws, 2012).  
 Maraviroc, another drug tested for use in PrEP, is a HIV 
entry inhibitor via blockage of CCR5 receptors (Coll et al., 
2015). Though some efficacy has been seen in rhesus 
macaques using a maraviroc based microbicide (discussed 
later in this review), oral maraviroc did not prevent simian-
HIV (SHIV) transmission (Massud et al., 2013). Additionally, 
Coll et al. (2015) recently showed that a single oral dose of 
maraviroc does not prevent rectal HIV transmission. 
 
MICROBICIDES FOR HIV PREVENTION 
The WHO describes microbicides as “compounds applied on 
the vagina or rectum to prevent STIs, including HIV”. They 
are available in different formulations including gels, 
suppositories, dissolving films, creams or sponges. 
Micobicides offer protection by providing a physical barrier 
between the pathogen and its target cells; by maintaining the 
natural level of vaginal pH thus enhance the natural vaginal 
defence mechanism; or by preventing pathogen replication. In 
this review, we classify microbicides according to whether or 
not they are ARV based. 
 
First Generation: Non-ARV Based Microbicides 
 
Surfactant Microbicides:  
Nonoxynol-9: Nonoxynol-9 (N-9) is a non-ionic detergent 
and the principal active ingredient in most over-the-counter 
spermicides. It had been used for contraception since 1950s 
but the need for a female controlled method to prevent HIV 
led to clinical trials looking into its effectiveness in a vaginal 
microbicide. Studies demonstrated that microbicides 
containing N-9 do not reduce the rate of STIs nor HIV 
infection (Richardson et al., 2001; Roddy et al., 1998; Kreiss 
et al., 1992). More dramatically, when used frequently by 
women at high-risk of infection, N-9 actually increased the 
rate of genital lesions and risk of gonorrhoeal infection 
(Richardson et al., 2001). Similarly, a randomised placebo-
controlled clinical trial conducted among FSWs from Benin, 
Côte d’Ivoire, South Africa and Thailand, found that multiple 
use of N-9 increased lesions and epithelial barrier disruption 
therefore enhancing HIV-1 infection (Van Damme et al., 
2017). In light of these findings, studies on N-9 to prevent 
HIV-1infection were stopped. 
 
C31G/Savvy: Savvy vaginal gel (C31G) had been shown, in 
vitro, to inhibit Chlamydia trachomatis infectivity (Wyrick et 
al., 1997). Two clinical trials conducted in Ghana and Nigeria 
to test the effectiveness of a 1% C31G gel to prevent HIV-1 
were both prematurely stopped due to futility. The studies 
cited that use of Savvy caused vaginal irritations which may 
have led to inflammation of the genital tract and pre-dispose 
the user to HIV-1 infection (Feldblum et al., 2008; Peterson et 
al., 2007). 
Though surfactants have the advantage of contraception and 
disruption of virus membrane, failure of N-9 and C31G 
highlighted that such compounds deleteriously impact healthy 
cells when used in microbicides. 
 
Blocking and Buffer Microbicides: 
Pro2000 and BufferGel: Pro2000 gel is a synthetic 
naphthalene sulphonate polymer with ability to bind CD4 and 
block binding of gp-120 (Rusconi et al., 1996) thus prevent 
attachment and entry of HIV into the cell. Although the gel 
has been shown to be safe and well tolerated among women 
(Guffey et al., 2014; Karim et al., 2011; McCormack et al., 
2010) and having anti-viral action in laboratory and non-
human primate experiments (Bourne et al., 1999); a 0.5% 
formulation indicated little (Karim et al., 2011) or no 
(McCormack et al., 2010) protective effect against HIV-1 
acquisition in humans. BufferGel, a vaginal gel that maintains 
an acidic vaginal pH has been shown protective against 
Neiserria gonnorhoeae and Chlamydia trachomatis infection 
in vitro and in some animal models (Spencer et al., 2004; 
Achilles et al., 2002) but not protective against HIV-1 
infection in women (Karim et al., 2011) . 
 
Cellulose Sulphate: Cellulose sulphate (CS), an antimicrobial 
agent also proved disappointing in search for an effective 
microbicide. Although safe and well tolerated (El-Sadr et al., 
2006), it showed no effect against STIs or HIV (Halpern et al., 
2008). Indeed, interim analysis of a multi-country trial showed 
that 13 more participants in a 6% CS treatment arm sero-
converted compared to the placebo arm (Van Damme et al., 
2008). Later Mesquita and colleagues showed that although 
CS was not cytotoxic, its use led to rapid and sustained 
disruption of tight mucosal junctions (Mesquita et al., 2009) 
and overall actually increasing the risk of HIV-1 infection. 
 
Carraguard: Carraguard is a sulphated polysaccharide used 
as a commercial additive. In vitro studies indicated that it 
could block cell line adhesion suggesting it could prevent 
mucosal transmission of HIV-1 (Pearce-Pratt and Phillips, 
1996). Mice and rabbit models also showed that Carragaurd 
prevented herpes simplex virus-2 (Zacharopoulos and 
Phillips, 1997) and human papilloma virus (Marais et al., 
2011) infection and did not have toxic effects nor cause 
mucosal irritation (Sudol and Phillips, 2004), but failed to 
show any efficacy for HIV-1protection in humans (Skoler-
Karpoff et al., 2008). 
These first generation microbicides did not confer protection 
against HIV infection and some, in fact, enhanced acquisition 
by causing epithelial barrier disruption. 
 
Second Generation: ARV Based Microbicides 
This new generation of microbicides, also termed ‘topical 
PrEP’ are specific to prevent HIV but do not offer protection 
against other STIs. 
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Tenofovir-based Microbicides: Overall, from the CAPRISA 
004 Microbicide clinical trial to analyse the efficacy of a 1% 
tenofovir gel formulation, HIV-1 infection reduced by 39% 
and by 54% among the women who adhered to the study 
protocol (Abdool Karim et al., 2010). 889 HIV-negative 
women from South Africa had been enrolled in this double-
blind randomised placebo controlled trial and randomly 
assigned to either 1% tenofovir gel or placebo gel arm. This 
was the first clinical trial to show that a microbicide could 
prevent HIV infection bringing hope for biomedical 
prevention. Recently, it was shown that the composition of the 
vaginal microbiome of the women enrolled in CAPRISA 004 
affected the efficacy of the tenofovir gel (Klatt et al., 2017). 
Nonetheless, the FACTS 001 clinical trial also among HIV-
negative sexually active women in South Africa, contradicted 
these findings, with 123 infections occurring during the trial 
(61 and 62 in the treatment and placebo arm respectively). 
Tenofovir effectiveness was however higher in about 20% of 
the women who used the product in more than 72% of their 
sex encounters (Rees et al., 2015). Similarly, both the oral and 
1% vaginal gel arms of tenofovir in the VOICE study were 
discontinued when interim analysis showed that neither 
formulation provided HIV-1 protection. Poor adherence to the 
intervention appeared to be the main reason for no effect 
(Mascolini, 2013). In light of VOICE and FACTS 001 results, 
it is unlikely that a 1% tenofovir gel will move forward as a 
microbicide. Adherence is brought out as an issue and the need 
to design microbicides that are long lasting and/or easier to 
integrate into the daily lives of women is emphasised. 
 
Dapivirine-based Microbicides: The idea to develop a longer 
lasting microbicide was pushed forward in two phase III sister 
clinical trials, the ASPIRE and The Ring Study, conducted in 
Zimbabwe, Uganda, South Africa and Malawi. Both enrolled, 
in total, of 4 500 women to study the safety and efficacy of a 
vaginal ring containing 25mg of dapivirine, a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) (Baeten et al., 2016). 
The ASPIRE study showed a 27% reduction in HIV-1 
incidence among the dapivirine treated group compared to the 
placebo; while 31% efficacy was observed in The Ring Study. 
Conversely, post-hoc analysis demonstrated up to 56% 
protection in women older than 21 years but no protection in 
younger women in ASPIRE and only 15% protection was 
observed in younger women in The Ring Study (International 
Partnership for Microbicides, 2016). Adherence to the 
intervention, biological differences between young and older 
women and/or number of sex acts with HIV-1 infected 
partners possibly explain this difference.  
ARV-based microbicides are better at HIV prevention, but 
adherence is still a major concern. Combining a microbicide 
with a contraceptive method may provide double-pronged 
benefit and increase adherence (‘After The Ring Study : 
DREAM’, 2017). 
 
Potential Microbicide Bases 
Some other products have been tested for use as microbicide 
bases, some, like maraviroc and glycerol monolaurate, seem 
promising though more research is required.  
 
Maraviroc: Rhesus macaques exposed to maraviroc vaginally 
were protected against a high-dose SHIV challenge in a dose 
dependant manner (Veazey et al., 2010). A phase I trial, 
conducted to determine the safety and pharmacokinetics of a 
ring containing maraviroc alone, dapivirine alone, dapivirine-
maraviroc combination or placebo, enrolled 48 women from 
USA and found that the combination ring was safe and well 
tolerated. However, while maraviroc was detected only in the 
vaginal fluid and at very low levels in cervical tissue, 
dapivirine was detected in plasma, vaginal secretions and 
cervical tissue. The combination ring is being reformulated to 
increase release of maraviroc (Chen et al., 2015). 
 
Glycerol monolaurate: Glycerol monolaurate (GML), also 
called monolaurin, is a fatty acid monoester commonly used 
as a food preservative and emulsifier in cosmetics 
(Bevilacqua, Sinigaglia and Corbo, 2008; Ruzin and Novick, 
2000). It is found naturally in coconut oil (Lieberman, Enig 
and Preuss, 2006) and human breast milk (Hegde, 2006; 
Peterson and Schlievert, 2006), thus is considered safe. In 
vitro, GML can inhibit bacterial growth (Peterson and 
Schlievert, 2006) at low concentrations and block bacterial 
exotoxin production (Schlievert et al., 2008). GML in a 
microbicide was first tested in rhesus macaque models and 
demonstrated neither modification of normal mucosal 
integrity nor inflammation (Schlievert et al., 2008). Further, 
Ashley Haase’s group showed that GML confers protection 
against high-doses of vaginally introduced SIV (Haase et al., 
2015; Li et al., 2009). This protective ability was associated 
with GML’s capacity to inhibit production of macrophage 
inhibitory protein (MIP)-3α and the pro-inflammatory 
cytokine interleukin (IL)-8, thus curtailing cell signalling 
pathways that recruit CD4 T-cells to the mucosal surface. The 
efficacy of GML in prevention of HIV infection in humans 
remains to be demonstrated. 
 Generally, although microbicides show protection 
potential, the need to develop a long-term HIV protective 
biomedical method such as a vaccine remains a public health 
priority. 
 
VACCINES FOR HIV PREVENTION 
Development of a vaccine could be the “final bullet” against 
HIV infection. Several candidate vaccines have been 
developed and tested. 
 
AIDSVAX: The VAX004, a phase III double-blinded vaccine 
trial, randomised 5 095 HIV-negative men and 308 women at 
high risk of infection to receive intramuscular injections of the 
recombinant gp-120 vaccine (AIDSVAX B/B; VaxGen) 
derived from 2 sub-type B HIV strains, or the placebo 
consisting of alum only (Group, 2005). There was no 
protective effect, with a 6.7% and 7.0% infection rate seen in 
the treatment and placebo group respectively. Similarly, 
another phase III trial by Pitisuttithum et al. (2006) conducted 
in Thailand tested the efficacy of a bivalent subtype B/E 
recombinant gp-120 HIV-1 vaccine (AIDSVAX B/E; 
VaxGen) among IDUs. This showed neither efficacy in 
preventing HIV-1 infection nor ability to impede disease 
progression.  
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STEP and Phambili Trials: The Merck Adenovirus Serotype 
5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5® HIV-1 
Gag/Pol/Nef), a DNA-based vaccine, was tested in the double 
blind STEP (HVTN 502/Merk V520-023) phase IIb trial 
initiated in 34 sites in the Americas, Australia and the 
Caribbean. 3 000 HIV-negative individuals at high risk of 
infection were randomised to receive 3 doses of either the 
vaccine or placebo at week 0, 4 and 26. Interim analysis 
indicated that 24 out of 741 infections occurred in the 
treatment arm and 21 out of 762 in placebo arm, each 
participant having received only one dose of either, and STEP 
was stopped. Although this vaccine was shown to elicit an 
interferon-gamma immune response in 75% of randomly 
selected samples, those who sero-converted during the study 
revealed no decrease in viral concentration, contradicting the 
expectation of a cell-mediated response to kill infected cells 
and reduce viral load (Buchbinder et al., 2008). The HVTN 
503/Phambili Study planned parallel to STEP in South Africa 
was also halted following results from interim results of STEP 
(Gray et al., 2011). 
 Interestingly, analyses from both trials indicated that HIV 
risk actually increased in the vaccine arms. Being 
uncircumcised and/or being adenovirus-5 (Ad5) sero-positive 
prior to vaccination was associated with this increased risk 
(Duerr, et al., 2012; Gray et al., 2011) and, enhanced 
activation of the immune system induced by the Ad5 vector 
shortly after vaccination may have caused increased number 
of HIV-1 target cells at the mucosal sites. In Phambili, 
vaccinated women who sero-converted had lower viral load 
and a slower CD4 T-cell decline compared to those in the 




This phase IIb, randomised, double-blind, placebo-controlled 
trial evaluated vaccine candidate in a prime-boost strategy 
among 2 504 HIV-negative circumcised MSM in USA 
(Hammer et al., 2013). The regimen was initiated with 3 
intramuscular injections of either the vaccine, the VRC-
HIVDNA016-00-VP containing 6 separate DNA plasmids 
including Gag, Pol, Nef genes from HIV-1 clade B and Env 
genes from HIV-1 clade A, B and C or placebo over an 8 week 
period. Twenty four weeks later, participants received a single 
injection of the boost vaccine consisting of Gag/Pol genes 
from HIV-1 clade B and Env genes from clade A, B and C 
delivered in an Ad5 vector or vector free placebo. The vaccine 
showed no protection against HIV with 41 new infections (27 
in vaccine group and 21 in placebo group) occurring; neither 
did it reduce viral load in those who were infected. 
 
RV-144 
To date, the only promising outcome of a HIV vaccine trial is 
from the RV-144 phase III clinical trial conducted in Thailand. 
This canarypox vector vaccine (ALVAC-HIV [vcp1521]) 
prime, plus the recombinant gp-120 sub-unit AIDSVAX® 
B/E boost vaccine indicated a 31.2% reduction in rate of HIV-
1 infection (Rerks-Ngarm et al., 2009). 16 402 healthy adults, 
enrolled and randomised, received four injections of either, the 
prime vaccine at weeks 0, 4, 12 and 24 plus boost 
immunizations at weeks 12 and 24; or placebo injections at 
same time points. Although the results were promising, RV-
144 did not show an effect on viral load among the individuals 
who sero-converted. Follow up studies indicated that 
protection was associated with the production of V2-specific 
antibodies against V1/V2 area of the viral envelope protein as 
well as some efficacy mediated by neutralising antibodies 
(Zolla-Pazner et al., 2013; de Souza et al., 2012; Karasavvas 
et al., 2012; Montefiori et al., 2012).  
 
HVTN 702 
Ongoing in South Africa, is a phase IIb/III clinical trial which 
aims to test the tolerability, safety and efficacy of ALVAC-
HIV [vcp2438] plus a bivalent Subtype C gp-120/MF59 
candidate vaccine in HIV-negative adults (Global Advocacy 
for HIV Prevention, 2017). Findings will provide more 
information to help perfect a much needed HIV-1 vaccine. 
Despite the number of candidate vaccines tested, some 
showing efficacy, none is ready for licensure as none offers a 
threshold of protection high enough to recommend for a large 
scale roll-out. CAPRISA 004 and RV-144 proved that a 
microbicide or vaccine against HIV is feasible, however 
further research is required to augment their efficacy. 
 
NEW FRONTIERS FOR BIOMEDICAL APPROACHES 
TO HIV PREVENTION 
Overwhelming evidence that increased immune activation and 
inflammation are risk factors for HIV infection is documented 
(Masson et al., 2014; Card, Ball and Fowke, 2013; Mitchell et 
al., 2008; Johnson and Lewis, 2008; Rebbapragada et al., 
2007; Corey et al., 2004; Corbett et al., 2002; Sturm-Ramirez 
et al., 2000; Giorgi et al., 1999, 1993; Liu et al., 1998). This 
aspect is also demonstrated through microbicide (Haase et al., 
2015; Masson et al., 2015; Naranbhai et al., 2012; Lozenski et 
al., 2012; Li et al., 2009; Fichorova, 2004; Fichorova, Tucker 
and Anderson, 2001) and vaccine studies (Duerr, et al., 2012). 
The link between HIV infection and immune activation is also 
emphasised among HIV-exposed seronegative (HESN) 
individuals (McKinnon et al., 2015; Card, Ball and Fowke, 
2013; MacKelprang et al., 2012; Lajoie et al., 2012; Songok 
et al., 2012; McLaren et al., 2010; Card et al., 2009; Jennes et 
al., 2006; Koning et al., 2005; Kaul et al., 1999; Fowke et al., 
1996). HESN demonstrate a lower baseline of immune 
activation than would be considered normal, a state called 
immune quiescence (Card, Ball and Fowke, 2013). With this 
in mind, could decreasing baseline immune activation be a 
useful element for HIV prevention?  
 Certain compounds known to alter the body’s immune 
system have been tested for their effects on HIV, for instance, 
type 1 interferon (IFN) blockers such as chloropromazine, 
bafilomycin and chloroquine which lower the production of 
IFNs and pro-inflammatory cytokines. Also, chloroquine 
(CQ) and its analogue hydroxychloroquine (HCQ) been 
shown to act as anti-HIV agents (Martinson et al., 2010; 
Beignon et al., 2005; Karres et al., 1998). In vitro studies 
indicated that CQ decreases formation of pro-viral DNA 
(Fesen et al., 1993) as well as inhibits HIV-1 integrase and 
Tat-mediated trans-activation of HIV-1 long term repeats 
(LTRs) (Savarino et al., 2001); thereby altering the 
immunogenic properties of gp-120 and decreasing HIV-1 
production. Additionally, CQ can inhibit metabolism of 
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arachidonic acid thereby inhibit Tat-mediated LTR driven 
gene expression of HIV-1 (Jiang, Lin and Chen, 1996). Piconi 
and colleagues (2011) showed that 6 month treatment with 
HCQ led to a significant decrease in proportion of 
proliferating lymphocytes (CD4+Ki67+) and activated 
monocyte (CD14+CD69+ cells); as well as increases of naive 
and activated T-regulatory levels in HIV-infected 
immunologic non-responders. This study also demonstrated 
reduction of IFN-α secreting pDCs plus interleukin (IL)-6 and 
TNF-α producing CD4+ and CD14+ cells.  
 Another group of compounds shown to reduce chronic 
immune activation are Cyclooxygenase type 2 (COX-2) 
inhibitors (Pettersen et al., 2011). Inhibition of COX-2 leads 
to decreased production of pro-inflammatory cytokines. An 
example is acetylsalicylic acid (aspirin) which decreases of 
pro-inflammatory prostaglandin E2, thromboxane B2 and IL-
2 production (Coe, Denison and McCabe, 2011) and increases 
production of lipoxin A4 (LXA4) and 15-epi-LXA A4 which 
are anti-inflammatory (Ariel et al., 2003; Planagumà et al., 
2002). The effect of these on HIV is however yet to be 
investigated. 
 Yet another group studied for suitability to reduce 
immune activation are statins (otherwise called 3-hydroxy-3-
methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors) 
for example rosuvastatin and atorvastatin, drugs which are 
used in cardiovascular disease management. Administered as 
a short term regimen, a high dose of atorvastatin was seen to 
reduce systemic activated CD4+ and CD8+ lymphocytes 
expressing cell activation marker HLA-DR (Ganesan et al., 
2011). Low dose rosuvastatin on the other hand showed no 
effect on T cell activation markers, suggesting that reduction 
of immune activation by statins is dose dependent (Weijma et 
al., 2016). 
 This concept of modulation of the body’s immune system 
to induce quiescence is not far-fetched and may be a possible 
novel facet to augment biomedical strategies for HIV 
prevention particularly among HIV-high-risk groups such as 
FSW and MSM.  
 
Conclusion 
Preventing HIV infection remains the foremost option to curb 
the HIV/AIDS epidemic. Although behaviour change strategies 
remain at the core, it is important to research into improving the 
efficacy of biomedical methods available and to develop novel 
modes of prevention. Strategies such as induction of Immune 
quiescence could add to the biomedical arsenal in the fight 
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